Analysis for IDXX

📈 Growth & Financial Trajectory

IDEXX's revenue rose from $975.5M in 2024 Q3 to $1,216.6M in 2026 Q2, about 25% growth across eight quarters. Net income grew from $232.8M to $338.4M (~46%), signaling durable earnings expansion. Gross margins remained robust at roughly 60-64%, with operating margins in the low-to-mid 30s%, indicating efficient leverage on higher volumes.

💰 Margins & Cash Flow

Operating cash flow remained strong, with notable figures such as $262.0M (2024 Q4) and $347.2M (2026 Q2) from operations. Gross margin resilience supports profitability even as R&D and benefits costs persist. Net cash flow was positive in most quarters, though 2026 Q2 shows a small overall outflow (-$3.6M), driven by heavy financing activity (-$325.2M) offset by investing cash flow (-$25.5M).

🛡️ Balance Sheet & Liquidity

Total assets sit around $3.3-3.4B, with Equity Attributable To Parent around $1.55-1.71B and Long-term Debt near $450M. Current liabilities run ~$1.1-1.3B, supporting a modest current ratio and solid liquidity against ongoing investments.

⚠️ Key Drivers & Risks

• Drivers: Durable demand in veterinary diagnostics, recurring consumables, strong cash generation enabling expansion.
• Risks: Dependency on animal-health cycles, currency exposure, valuation sensitivity to growth expectations.